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Abstract
Transient receptor potential channels are important mediators of thermal and mechanical stimuli and play an important role in
neuropathic pain. The contribution of hereditary variants in the genes of transient receptor potential channels to neuropathic pain is
unknown. We investigated the frequency of transient receptor potential ankyrin 1, transient receptor potential melastin 8 and
transient receptor potential vanilloid 1 single nucleotide polymorphisms and their impact on somatosensory abnormalities in
neuropathic pain patients. Within the German Research Network on Neuropathic Pain (Deutscher Forscbungsverbund
Neuropathischer Schmerz) 371 neuropathic pain patients were phenotypically characterized using standardized quantitative
sensory testing. Pyrosequencing was employed to determine a total of eleven single nucleotide polymorphisms in transient
receptor potential channel genes of the neuropathic pain patients and a cohort of 253 German healthy volunteers. Associations of
quantitative sensory testing parameters and single nucleotide polymorphisms between and within groups and subgroups, based
on sensory phenotypes, were analyzed. Single nucleotide polymorphisms frequencies did not differ between both the cohorts.
However, in neuropathic pain patients transient receptor potential ankyrin 1 710G.A (rs920829, E179K) was associated with the
presence of paradoxical heat sensation (p=0.03), and transient receptor potential vanilloid 1 1911A.G (rs8065080, I585V) with cold
hypoalgesia (p=0.0035). Two main subgroups characterized by preserved (1) and impaired (2) sensory function were identified. In
subgroup 1 transient receptor potential vanilloid 1 1911A.G led to significantly less heat hyperalgesia, pinprick hyperalgesia and
mechanical hypaesthesia (p=0.006, p=0.005 and p,0.001) and transient receptor potential vanilloid 1 1103C.G (rs222747,M315I)
to cold hypaesthesia (p=0.002), but there was absence of associations in subgroup 2. In this study we found no evidence that
genetic variants of transient receptor potential channels are involved in the expression of neuropathic pain, but transient receptor
potential channel polymorphisms contributed significantly to the somatosensory abnormalities of neuropathic pain patients.
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Introduction
Neuropathic pain arises after lesions or diseases of the
somatosensory nervous system and involves multiple somatosen-
sory phenomena. In addition to spontaneous pain, these include
negative and positive symptoms and signs such as hypaesthesia,
hypoalgesia, thermal and mechanical hyperalgesia and allodynia
[1]. These somatosensory abnormalities and their combination,
i.e. the somatosensory profile, may mirror the underlying pain-
generating mechanisms [1]. The German Research Network on
Neuropathic Pain (DFNS) developed a standardized quantitative
sensory testing (QST) battery for somatosensory phenotyping of
neuropathic pain patients, including healthy control reference
data, facilitating the routine clinical assessment [2,3].
The understanding of the molecular basis of neuropathic pain has
been expanded by the cloning and characterization of the transient
receptor potential (TRP) family of voltage-gated ion channels.
Among these the TRP vanilloid 1 (TRPV1), TRP melastin 8
(TRPM8) and TRP ankyrin 1 (TRPA1) subfamilies have been
found to play important roles in transduction and sensitisation in
primary afferent somatosensory neurons [4]. TRPV1 is involved in
the transduction of noxious heat and a receptor for capsaicin, thus
mediating heat hyperalgesia after stimulation with this hot chilli
constituent [5]. It is expressed on small diameter nociceptive
neurons, likely to be C-fibers [6]. TRPM8 is also expressed on small
and medium diameter sensory neurons, likely to be C and A-delta
fibers. It is strongly activated by its agonist menthol and serves as a
major cold and cooling transduction channel [7,8]. TRPA1,
activated by its agonists cinnamon and mustard oil, transduces
cold and mechanical stimuli. Moreover, on the peptide level it is
20% homologous to TRPV1 and is co-expressed with TRPV1 in a
subpopulation of unmyelinated nociceptive neurons suggesting an
important role in nociception [9].
Beside these physiological functions, TRPs are thought to play
an important role in the generation of neuropathic pain, as
demonstrated by in vitro and in vivo animal studies and
neurophysiological and psychophysical studies in human experi-
mental pain models and pain patients [10]. TRP channels have
been shown to be differentially expressed following experimental
nerve injury [11,12]. Moreover, enhanced expression of TRP
channels on neighbouring undamaged fibres following peripheral
nerve injury was previously described to regulate pain behaviour
[11,12]. TRPV1 was shown to be involved in the activation and
sensitisation of primary sensory neurons to heat, acid and different
endogenous inflammatory mediators, leading to heat and
mechanical hyperalgesia and spontaneous pain. Likewise TRPM8
contributes to cold pain, cold hyperalgesia and allodynia and
TRPA1 leads to activation, sensitisation and facilitation of
nociception like TRPV1 [11,12].
However, the contribution of a genetic variability in TRP
channels on pain perception and pain generation in neuropathic
pain patients is unknown. In this study we describe the results of an
association analysis of polymorphisms in TRPV1, TRPM8 and
TRPA1 genes with somatosensory signs of neuropathic pain
patients. The aims were (1) to determine the frequencies of TRP
variants in a large group of neuropathic pain patients of different
aetiology and a cohort of healthy volunteers and (2) to determine
the relationship of TRP gene variants and somatosensory function
in neuropathic pain patients. Within this study we could
demonstrate significant associations between the somatosensory
function and TRP gene variants in neuropathic pain patients but
no differences in the TRP frequencies compared with healthy
volunteers.
Methods
Ethics statement
All subjects gave their written informed consent and the study
was approved by the ethics committee of the Medical Faculty of
the Christian-Albrechts-University Kiel and subsequently the
Ethic Committees of the other participating DFNS centers and
performed according to the Declaration of Helsinki.
Study populations
A total of 371 patients with chronic neuropathic pain syndromes,
all Caucasians, who participated in the German Research Network
on Neuropathic Pain (DFNS; www.neuro.med.tu-muenchen.de/
dfns/) were included in the study (210 female, 161 male). The
patients suffered from complex regional pain syndrome, posther-
petic neuralgia, peripheral nerve injury, trigeminal neuropathy,
polyneuropathy, central pain and neuropathies that did not fulfill
diagnostic criteria of the above mentioned syndromes as diagnosed
by expert physicians. Patient characteristics are listed in Table 1.
For comparison of allelic frequencies of target polymorphisms, 253
healthy German volunteers (173 female, mean age 26.866.9 years;
80 male, mean age 28.467.0 years), all Caucasian, were included.
Phenotypical characterization (quantitative sensory
testing)
All patients were phenotypically characterized using standardized
quantitative sensory testing (QST) established by the DFNS to
determinate somatosensory function and signs of pain [2]. This QST
battery consists of seven tests that assess 13 parameters. Briefly,
thermal detection thresholds for the perception of cold (CDT) and
warm (WDT), thermal pain thresholds for cold (CPT) and heat
(HPT), paradoxical heat sensation (PHS), mechanical detection
thresholds for touch (MDT) and vibration (VDT), mechanical pain
sensitivity including thresholds for pinprick (MPT) and blunt pressure
(PPT), a stimulus-response-function for pinprick sensitivity (MPS) and
dynamic mechanical allodynia (DMA) as well as pain summation to
repetitive pinprick stimuli (wind-up ratio; WUR) were determined in
the area of pain. Patient data were included in the study analysis, if at
least results of 12 QST tests were available.
Genetic analysis
Whole genomic DNA was extracted from venous blood samples
obtained from patients and volunteers using the Qiagen Gentra
Puregene Blood Kit (Qiagen, Hilden, Germany). The final concen-
tration of gDNAwas determined spectrophotometrically. Two SNPs in
TRPV1, six in TRPM8 and three in TRPA1 genes were identified by
literature review in the context of neuropathic pain and selected for
detailed association analysis (Table 2). Except of TRPM8 787A.T
and TRPM8 790G.C (both synonymous polymorphisms detected in
parallel in our genotyping assay), all SNPs were carefully selected based
on the assumption that missense variants may have functional
consequences (detailed information are included in the Discussion
section). Genotyping of the TRP polymorphisms was performed by
pyrosequencing according to protocols provided by the manufacturer
on a PSQ HS96 platform (Biotage AB, Uppsala, Sweden). Primer
sequences and conditions are available on request.
Statistical analysis
Before statistical analysis the QST values that did not show normal
distribution (all except CPT, HPT, VDT and PHS) were transformed
logarithmically [2]. Subsequently, Z-scores were calculated, except
for DMA and PHS that are given with original values (DMA: 0–100
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numeric rating scale; PHS: numbers of PHS, 0–3) [2]. Z-scores above
‘‘0’’ indicate a gain of function (hyperalgesia, allodynia), while a Z-
score below ‘‘0’’ indicates a loss of function (hypaesthesia,
hypoalgesia). Pathological values were determined according nor-
mative data (95% confidence interval =Z-score of 061.96). Addi-
tionally, DMA and PHS were encoded as dichotomized values
(1=pathological, 0=within normal range).
In order to identify major subpopulations of patients who are
characterized by a typical combination of signs, a cluster analysis
was performed in those patients only from whom complete QST
results were available (241 of 371 patients, Table 1). The commonly
recommended WARD-approach with an Euclidian distance
measure was used as described elsewhere [13]. Only those clusters
determined within the first WARD fusion algorithm calculation
were used. The clusters represent significantly different somatosen-
sory QST Z-profiles demonstrating cluster specific sensory profiles.
The statistical software SPSS 17.0 was employed for all
statistical evaluations. Genotype, respectively allele distributions,
in the population of patients and healthy controls as well as
differences of dichotomised QST values related to target
polymorphisms were assessed with Chi-square and Yates corrected
Chi-square test respectively. Differences in measured QST
parameters (means of Z-scores) and for bi-allelic polymorphisms
each subtest and genotype were calculated using analysis of
variance (ANOVA). For dominant and recessive models the t-test
was used, if applicable. To correct for multiple testing each test
was performed using 100,000 permutations.
Results
Genotype distribution
The frequency distribution of all polymorphisms investigated
was in Hardy-Weinberg equilibrium. Moreover, after correcting
for multiple comparisons, the frequency of all SNPs did not differ
significantly between neuropathic pain patients, healthy controls
and data from the HapMap project (Table S1).
Association of TRP gene variants to QST Z-scores
First, within the group of patients who suffered from
paradoxical heat sensation (PHS) heterozygous and homozygous
carriers of the TRPA1 710G.A variant were significantly under-
represented as compared to neuropathic pain patients without
PHS (odds ratio 0.44, 95% confidence interval 0.21–0.90,
p = 0.03) (Fig. 1). Second, homozygous variant carriers (GG) of
the TRPV1 1911A.G polymorphism exhibited significant cold
hypoalgesia compared with heterozygous or wild type carriers
(CPT Z-scores: 20.1361.10, 0.1961.20, and 0.1861.14, respec-
tively; p = 0.003).
Somatosensory profiles of subpopulations
Hierarchical cluster analysis detected two main clusters (Fig. 2).
Cluster 1 includes a group of patients with mainly preserved
sensory function, while cluster 2 was characterized by a relative
loss of small and large fiber function as detected by significant
lower Z-scores of CDT, WDT, TSL, MDT (p,0.0001), VDT
(p= 0.002) and a higher Z-score of WUR (p= 0.027) in patients
Table 2. Significant associations of TRPV1 variants and
somatosensory function.
QST test
CDT HPT MDT MPS
1103C.G CC/CG/GG 0.00231
CC/CG+GG 0.00192
CC+CG/GG 0.00182
1911A.G AA/AG/GG 0.00591 0.00041 n.s.1
AA/AG+GG n.s.2 ,0.00012 0.0052
AA+AG/GG 0.00062 n.s.2 n.s.2
Significant associations of selected TRPV1 variants with three parameters of
quantitative sensory testing (CDT, cold detection threshold, HPT, heat pain
threshold, MDT, mechanical detection threshold) in 121 patients belonging to
cluster 1. Z-score means of each QST parameter were correlated with genotypes
applying a dominant or recessive model.
1ANOVA test,
2t-test.
doi:10.1371/journal.pone.0017387.t002
Table 1. Demographic data of patients.
All neuropathic pain
patients Cluster 1 Cluster 2
p-values
Cluster 1 vs. Cluster 2
N 371 121 120
Age (years) 56.4614.4 52.2613.7 56.6613.8 p,0.02
Females (%) 57.7 56.1 49.1 p = 0.34
Disease duration (months) 43.9671.9 39.1678.6 35.1647.4 p = 0.63
Pain intensity (0–10 Likert scale NRS) 6.062.0 6.062.0 6.062.0 p = 1.00
Polyneuropathy (n, %) 101 (27.2) 24 (19.8) 41 (35.0) p,0.02
Post herpetic neuralgia (n, %) 35 (9.4) 7 (5.8) 14 (11.6) p = 0.16
Painful nerve injury (n, %) 34 (9.2) 13 (10.7) 14 (11.6) p = 0.98
CRPS (n, %) 87 (23.5) 40 (33.1) 29 (24.1) p = 0.17
Trigeminal pain (n, %) 57 (15.4) 28 (23.1) 7 (5.8) p,0.0001
Central pain (n, %) 24 (6.5) 4 (3.3) 7 (5.8) p = 0.53
Other neuropathy (n, %) 33 (8.9) 5 (4.2) 8 (6.1) p = 0.56
Values are given as means6 single standard deviation, percentages or absolute values respectively. Pain intensity of the last four weeks was assessed using the numeric
rating scale (NRS; 0 = no pain, 10 =worst pain imaginable).
doi:10.1371/journal.pone.0017387.t001
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who belong to cluster 2 as compared to cluster 1. DMA and PHS
differed significantly between the two clusters. Pathological PHS
occurred significantly more frequent in cluster 2 (odds ratio 3.44,
95% CI 1.78–6.68, p,0.0001) and DMA was more frequent in
cluster 1 (odds ratio 2.30, 95% CI 1.30–4.07, p = 0.004).
Association of TRP gene variants to QST Z-scores of
subpopulations
Z-scores of all QST tests were stratified to all TRP variants
investigated in the entire sample and in both clusters. After
correcting for multiple comparisons, two TRPV1 polymorphisms,
Figure 1. Association of TRPA1 710G.A to appearance of paradoxical heat sensation. Patients with positive paradoxical heat (PHS)
showed a lower frequency of variant TRPA1 710 genotypes (GA+AA carriers) compared to patients with negative PHS (odds ratio 0.44, 95%
confidence interval 0.21–0.90, p = 0.03).
doi:10.1371/journal.pone.0017387.g001
Figure 2. Somatosensory profiles of cluster 1 and cluster 2. Cluster 1 is characterized by a predominant preserved somatosensory function
whereas cluster 2 exhibits relative loss of small fiber and large fiber function (lower Z-scores for CDT, WDT, TSL, MDT, VDT and WUR respectively).
Values are given as arithmetic mean and standard error of mean. The grey marked area displays the normative range (Z-scores between +/21.96).
P-values: *,0.05, **,0.01, ***,0.001.
doi:10.1371/journal.pone.0017387.g002
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1911A.G and 1103C.G, were identified that had a significant
relationship with the somatosensory function in cluster 1 (Table 2).
The TRPV1 1911A.G polymorphism was significantly associ-
ated with altered heat pain thresholds (HPT). Neuropathic pain
patients being heterozygote or with wild type TRPV1 1911G
genotype (AA or AG) tended to show heat hyperalgesia whereas
TRPV1 1911G homozygotes exhibited significantly higher, i.e.
normal heat pain thresholds (p= 0.0006; Fig. 3, 4). TRPV1
1911A.G was also identified to be associated significantly to
mechanical pain sensitivity (MPS; p= 0.005). The presence of at
least one G-variant allele was associated with lower, i.e. normalized
mechanical pain sensitivity to pinprick stimuli (MPS; Fig. 3, 4).
Moreover, TRPV1 1911A.G wild type carriers (AA) showed
higher mechanical detection thresholds (MDT), i.e. mechanical
hypaesthesia, than variant subjects (p,0.0001; Fig. 3, 4).
In contrast to TRPV1 1911A.G, the 1103C.G SNP was
significantly associated with cold detection threshold (CDT,
p= 0.0023). Homozygous variant carriers (GG) exhibited cold
hypaesthesia compared with heterozygous or wild type carriers
(p = 0.0018; Fig. 5).
Analyses within cluster 2 did not show any genotype-dependent
association with any QST parameter (Fig. 6). Due to the small sample
size, no analysis of possible associations of the different neuropathic
pain syndromes and QST parameters were performed.
Figure 3. The influence of TRPV1 1911 A.G on QST parameters in cluster 1. The influence of the TRPV1 1911A.G genotype on the
somatosensory profile as detected by QST in the patients of cluster 1 is shown. Homozygote variant carriers expressed significant lower, i.e. normal, Z-
scores for HPT (p = 0.0006). The second genotype-affected QST parameter is MDT. The higher Z-scores for MDT, i.e. less mechanical hypaesthesia to
non-painful mechanical stimuli, correlated with the presence of G-variant allele in TRPV1 1911A.G (p,0.0001). Third, lower Z-scores of mechanical
pain sensitivity (MPS), i.e. less pinprick hyperalgesia, were associated with the presence of at least one G-variant allele in TRPV1 1911A.G (p= 0.005).
Values are given as arithmetic mean and standard error of mean. P-values are shown for significant genotype-phenotype associations: **,0.01,
***,0.001.
doi:10.1371/journal.pone.0017387.g003
Figure 4. Associations of TRPV1 1911 A.G with HPT, MPS and MDT in cluster 1. Z-scores of heat pain threshold (HPT), mechanical pain
sensitivity (MPS) and mechanical detection threshold (MDT) stratified to TRPV1 1911G.A. HPT: Homozygous variant GG carriers exhibited
significantly lower, i.e. normal, Z-scores than carriers of the heterozygote or wild type genotype, which tended to show heat hyperalgesia. MPS:
Presence of at least one G-variant allele resulted in a decreased Z-score indicating less pinprick hyperalgesia.MDT: Presence of at least one G-variant
allele was associated with less mechanical hypaesthesia to non-painful mechanical stimuli resulting in higher Z-scores. Z-scores are given as median
with quartiles and ranges, p-values were calculated with t-test and corrected for multiple testing by permutation testing.
doi:10.1371/journal.pone.0017387.g004
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Discussion
The major finding of this study is that TRP channel
polymorphisms modulate the somatosensory function in neuro-
pathic pain patients. Since there were no significant differences in
the allelic distribution between neuropathic pain patients and
healthy volunteers it appears unlikely that the variants play a role
as susceptibility factors of chronic neuropathic pain.
Association of TRPA1 710G.A with paradoxical heat
sensation
Different mechanisms contribute to paradoxical heat sensation, i.e.
the perception of painful heat when a cold stimulus is applied. First, A-
delta fiber impairment, clinically manifest in a disturbed cold
sensation, is thought to disinhibit C-nociceptors by mechanisms of
gate control in the dorsal horn of the spinal cord leading to PHS
[14,15]. This hypothesis is supported by observations in the
experimental human pain model of selective A-fiber blockade and
in patients with peripheral neuropathy [14,16]. Second, dysfunction of
thalamic cells leads to disinhibition of central heat transmission
pathways, resulting in PHS e.g. in patients with multiple sclerosis
[17,18]. The frequency of TRPA1 710G.A variant carriers was
higher in PHS cases. Although the functional significance of this
polymorphism has not yet been investigated in vitro so far, it can be
hypothesized that the amino acid exchange from hydrophilic
glutamate to hydrophobic lysine in codon 237 may result in a
conformational change of the protein secondary structure. With
respect to the clinical observation, a loss of function appears to be likely
and thus result in an impairment of cold nociceptor sensitivity. This
might lead to a decreased input to the central nociceptive pathway
that is the same pathway for the conduction of heat and PHS. This
would, according to the hypotheses described above, lead in turn to a
lower likelihood of an effective disinhibition and thereby PHS.
Similar to the TRPV1 receptor, TRPA1 is known to sensitize
sensory neurons after nerve injury and contribute to altered pain
sensation in a familial episodic pain syndrome [19]. Therefore,
wild type carriers of the active TRPA1 710 might have a higher
propensity for sensitisation of nociceptors peripherally and/or
centrally, increasing the likelihood of PHS compared to carries of
the variant genotype. Interestingly, a psychophysical study in
CRPS patients demonstrated that PHS is a frequent finding in
acute CRPS [20] and inflammation is thought to be a dominant
cause of sensitisation in acute CRPS patients [21]. Possibly
TRPA1 contributes to this proposed mechanism in CRPS, since
TRPA1 is activated in models of inflammatory pain and leads to
pain and hyperalgesia [11,12].
Figure 5. The effect of TRPV1 1103 C.G on detection of non-
painful cold. The box plots show the cluster 1 specific association of
TRPV1 1103C.G SNP with the cold detection threshold (CDT).
Homozygous variant carriers exhibited cold hypaesthesia, i.e. lower Z-
score, compared with heterozygous or wild type carriers. Z-scores are
given as median with quartiles and range. P-values were calculated with
t-test and corrected for multiple testing by permutation testing.
doi:10.1371/journal.pone.0017387.g005
Figure 6. The influence of TRPV1 1911 A.G on QST parameters in cluster 2. The influence of the TRPV1 1911A.G genotype on the
somatosensory profile as detected by QST in the patients of cluster 2 is shown. The hereditary impact on somatosensory functions was detectable in
cluster 1 only. No significant associations were detected in cluster 2. Values are given as arithmetic mean and standard error of mean.
doi:10.1371/journal.pone.0017387.g006
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Association of TRPV1 1911A.G with cold pain threshold
At first sight the association of TRPV1 variants to CPT may
sound paradox, since TRPV1 is known as a heat sensor. However,
our observation is in line with earlier findings by Kim and
coworkers [22] who demonstrated in healthy volunteers that
homozygote TRPV1 1911A.G variant carriers exhibited longer
cold withdrawal times to ice water immersion of one hand, i.e.
higher cold pain tolerance. In our study, the Z-score of the cold
pain threshold in 1911GG carriers was lower than in AG and AA
carriers (20.1361.10 vs. 0.1961.20 and 0.1861.14 respectively)
indicating cold hypoalgesia.
TRPV1 1911A.G causes an isoleucine-valine exchange, both
hydrophobic amino acids. Though the variant 1911G was
associated with elevated protein levels in a human kidney cell
line expression system [23], the investigation of functional
responses to capsaicin, pH and temperature in whole-cell patch-
clamp and calcium imaging experiments suggests no critical
alteration of receptor structure and function with respect to this
receptor variant [24]. Another explanation for the effect of
TRPV1 on cold pain thresholds could be a possible interaction of
TRPV1 and the cold sensor TRPA1 since both are co-expressed in
sensory neurons [11,12]. However, functional and linkage studies
are currently lacking. Therefore our finding requires further
confirmation.
Associations in phenotypic subpopulations
We were able to allocate the phenotypically characterized
patients to two different clusters. Patients in a cluster share sensory
symptoms and signs and thus may share similar underlying
pathological mechanisms [25]. Interestingly, in a study that
investigated nerve and skin preparations of patients who suffered
from various neuropathic pain syndromes, TRP channels have
been found to be differentially expressed [26], thus supporting the
approach of stratification. One may hypothesize that in those
patients in whom TRPs are still preserved or increasingly
expressed SNP polymorphisms contribute to the somatosensory
function, whereas those who show a depletion of e.g. nerve growth
factor (NGF), the membrane density of TRP channels is likely to
be decreased [27]. Interestingly, Facer and coworkers [26] found
TRPV1 to be reduced in diabetic neuropathy patients. Accord-
ingly, in cluster 2 where the number of polyneuropathy patients
was significantly higher as in cluster 1, we did not find any
association between TRP variants and somatosensory function.
As mentioned above, TRPV1 1911A.G has not been shown to
alter TRPV1 function in vitro or in vivo [24]. However, in this
study it clearly modified different somatosensory functions in
patients allocated to cluster 1.
TRPV1 is a heat sensor and contributes to the sensitisation of
peripheral nociceptors in neuropathic pain [11,12]. The corre-
sponding clinical sign is heat hyperalgesia [1]. Peripheral
sensitisation of TRPV1 sensitive nociceptors in turn leads to
sensitisation of the central nociceptive system and clinically to
mechanical hyperalgesia [1]. Due to central adaptive mechanisms
tactile hypaesthesia accompanies mechanical hyperalgesia [28].
Thus, each sensory finding is compatible with neurobiological and
neuropharmacological mechanisms that can also be studied in
human surrogate models of neuropathic pain, e.g. capsaicin model
that involve a reversible modulation of the nociceptive system
[29,30]. These observations are in line with our findings on the
TRPV1 1911 genotype. Wild types or heterozygotes showed heat
hyperalgesia, mechanical hyperalgesia and mechanical hypaesthe-
sia in comparison to variant carriers that showed normalised
sensitivity to heat pain (HPT), mechanical pain detection (MPT)
and tactile sensation (MDT) (Figure 3, 4). Thus, the variant
TRPV1 1911A.G may prevent from peripheral and secondary
central sensitisation in patients with chronic neuropathic pain.
The second TRPV1 SNP of interest, namely TRPV1
1103C.G was significantly associated with cold hypaesthesia.
The SNP causes a methione-isoleucine exchange and in-vitro
investigation demonstrated an increased channel activity [23].
However since no effect of TRPV 1103C.G on HPT was
observed, the question arises if this observation might be explained
by a functional interaction of TRPM8 and TRPV1 that leads to
increased functional inhibition of the TRPM8 by this SNP
[31,32].
Study limitations
There are three main limiting factors of this study. First, the
number of SNP selected for this study was limited to missense
variants. No intronic, promoter, 59- or 39-UTR variants were
included as no association to pain or functional characterization
could be shown so far [33]. The functional significance of the
missense variants found to be associated with sensory function in
our study, has not yet been characterized in vitro. Thus the
findings are only based on a genetic association analysis. However,
our statistical analysis was conducted conservatively using - among
others - permutation corrections that still led to significant
associations and thus makes chance findings less likely. Second,
these associations need to be cross-validated in larger samples.
However, to our knowledge, there is currently no patient cohort
available outside the DFNS that used a comparable phenotyping
method. Hopefully, within the European Pain Consortium, a
second cohort will evolve, making soon further genetic association
studies and cross-validation possible. Third, no conclusions on the
role of these TRP polymorphisms in other ethnic groups can be
drawn, as it was recently demonstrated that African Americans
exhibit differential response to the topical application of the
TRPV1 agonist in capsaicin compared to three other ethic groups
[34].
Research and clinical perspectives
Our results demonstrate the need for further research on the
functionality of TRP genetic variants on sensory function and
nociception. Further on, our results open new avenues for the
treatment of neuropathic pain patients. First, specific TRPV1, TRPM8
and TRPA1 antagonists are under research as new therapeutic
options, with the analgesic TRPV1 agonist capsaicin already available
[35–37]. Second, it has to be clarified how far genetic variants of TRP
channels may account for response, non-response or symptom-specific
efficacy. This would suggest the subgrouping of patients along clinically
relevant markers when they enter clinical trials and follow-up trials
[38]. Moreover, variants identified here may serve as detectable risk
factors for the course of the disease and gene tests on specific SNPs
might serve as predictors of pain qualities in the future.
Supporting Information
Table S1 Frequencies of selected TRP channel gene variants in
371 neuropathic pain patients and 253 healthy volunteers. P-
values between genotypes of patients and controls are corrected for
multiple testing using 100,000 permutations.
(DOC)
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